Stock 2487 CUTIA THERAPEUTICS
Add to a list
To use this feature you must be a member
Log inSign up

News Cutia Therapeutics

Equities

2487

KYG2606C1006

Market Closed - Hong Kong S.E.
Other stock markets
 09:08:04 19/06/2024 BST 		5-day change 1st Jan Change
6.47 HKD +1.09% Intraday chart for Cutia Therapeutics +0.94% -41.07%
06-11 Certain Ordinary Shares of Cutia Therapeutics are subject to a Lock-Up Agreement Ending on 11-JUN-2024. CI
05-31 Cutia Therapeutics Presents Acne Drug's Phase III Clinical Trial Results at Asian Dermatology Congress MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Certain Ordinary Shares of Cutia Therapeutics are subject to a Lock-Up Agreement Ending on 11-JUN-2024.
CI
Cutia Therapeutics Presents Acne Drug's Phase III Clinical Trial Results at Asian Dermatology Congress
MT
Cutia Therapeutics Obtains Clinical Trial Approval in China for Dermatitis Drug
MT
Cutia Therapeutics Announces Investigational New Drug Application of CU-10101 for Atopic Dermatitis Approved by the Center for Drug Evaluation of the National Medical Products Administration of the People's Republic of China
CI
Cutia Therapeutics' Unit Receives Jiangsu Drug Manufacturing Certificate
MT
Cutia Therapeutics Submits NDA for Androgenetic Alopecia Treatment Spray; Shares Jump 6%
MT
Cutia Therapeutics Submits New Drug Application for Cu-40102 (Topical Finasteride Spray) in Hong Kong, PRC
CI
Cutia Therapeutics Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Cutia Therapeutics' Atopic Dermatitis Drug's IND Application Accepted by China's NMPA
MT
Cutia Therapeutics Announces the Investigational New Drug Application of CU-10101 (Topical Novel Small Molecule Agent) for the Treatment of Mild to Moderate Atopic Dermatitis Accepted by the Center for Drug Evaluation of the National Medical Products Administration
CI
Cutia Therapeutics Included in Two FTSE Indices
MT
Cutia Therapeutics Announces Completion of Phase I Clinical Trial of CU-20401
CI
Cutia Therapeutics Included in Hang Seng Family of Indexes
MT
Cutia's Phase 3 Clinical Trial for Analgesic Cream Reaches Primary Endpoint; Shares Surge 12%
MT
China Accepts Cutia Therapeutics's New Drug Application for Alopecia Treatment; Shares Surge 13%
MT
Cutia Therapeutics Announces New Drug Application for CU-40102 (Topical Finasteride Spray) Accepted by the National Medical Products Administration
CI
Cutia Therapeutics Doses First Patient for Anti-Obesity Injectable
MT
Cutia Therapeutics Announces First Patient Enrollment in the Phase II Clinical Trial of CU-20401
CI
Cutia Therapeutics Publishes Results of Phase 3 Trial for Alopecia, Acne Treatments in China
MT
Cutia Therapeutics Announces Results of Phase III Clinical Trials of CU-40102 (Topical Finasteride Spray) and CU-10201 (Topical 4% Minocycline Foam) in the People's Republic of China
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 2487 Stock
  4. News Cutia Therapeutics
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW